Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00239538 · ClinicalTrials.gov registry record · Phase 4
SMOOTH - Blood Pressure Control in Diabetic/Obese Patients
A Phase 4 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 4
- Development phase
- 840
- Enrollment target
NCT00239538 is a Phase 4 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 840 participants.
The verdict
NCT00239538, a Phase 4 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 840 participants
- Enrollment target
Study Summary
The primary objective of this study is to demonstrate that telmisartan 80 mg combined with hydrochlorothiazide 12.5 mg (T80/H12.5) is at least as effective and possibly superior to valsartan 160 mg combined with hydrochlorothiazide 12.5 mg (V160/H12.5) in lowering mean ambulatory systolic blood pressure (SBP) and diastolic blood pressure (DBP) during the last 6 hours of the 24-hour dosing interval at the end of a 10-week treatment period in mild-to-moderate hypertensive, overweight or obese patients with type 2 diabetes mellitus
Interventions
- DRUG telmisartan combined with hydrochlorothiazide (80/12.5 mg)
- DRUG valsartan combined with hydrochlorothiazide (160/12.5mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 840 participants |
| Start Date | 2003-01 |
| Est. Completion | 2004-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00239538
The ClinicalTrials.gov registry entry for NCT00239538 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 840 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which telmisartan combined with hydrochlorothiazide (80/12.5 mg) is the first listed.
NCT00239538 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00239538 about?
NCT00239538 is a clinical study titled "SMOOTH - Blood Pressure Control in Diabetic/Obese Patients". The primary objective of this study is to demonstrate that telmisartan 80 mg combined with hydrochlorothiazide 12.5 mg (T80/H12.5) is at least as effective and possibly superior to valsartan 160 mg combined with hydrochlorothiazide 12.5 mg (V160/H12.5) in lowering mean ambulatory systolic blood pres...
What is the current status of trial NCT00239538?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 840 participants. The study started on 2003-01. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00239538?
The interventions under investigation include: telmisartan combined with hydrochlorothiazide (80/12.5 mg) (DRUG), valsartan combined with hydrochlorothiazide (160/12.5mg) (DRUG).
Who is sponsoring clinical trial NCT00239538?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.